相关实验视频

Updated: Jan 10, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

新型奥龙衍生物通过AMPK-ACC-PPARα轴改善MASH脂质代谢

Sule Bai¹, Yi Zou¹, Wenyi Zhang¹

¹School of Biological Engineering, Tianjin University of Science and Technology, Tianjin 300457, China.

International journal of molecular sciences

|November 27, 2025

概括

化合物1d是一种新的泛PPAR激动剂,通过通过AMPK-ACC-PPARα轴改善肝脂代谢并减少炎症,有效地治疗与代谢功能障碍相关的脂肪肝炎 (MASH). 这突显了它作为一种新的MASH疗法的潜力.

科学领域:

肝病学肝病学是一种肝病学.
代谢障碍代谢障碍代谢障碍
药理学药理学是指药理学的学科.

背景情况:

代谢功能障碍相关的脂肪肝炎 (MASH) 是一种严重的肝脏疾病,由脂质代谢中断和炎症驱动.
目前对MASH的治疗策略有限,需要开发新的治疗方法.
在MASH中,有前途的泛PPAR激动剂,化合物1d的作用机制在很大程度上仍未被探索.

研究的目的:

阐明MASH中化合物1d的治疗机制.
为了研究化合物1d对肝脂代谢和炎症的影响.
评估化合物1d作为MASH的潜在治疗候选物.

主要方法:

在实验室和体内研究中,使用MASH小鼠模型进行了实验.
评估了化合物1d对AMPK-ACC-PPARα信号通路的影响.
分析了肝脂代谢标志物 (例如FASN) 和炎症标志物.

主要成果:

化合物1d在MASH模型中显著改善了乱的肝脂代谢.
它通过调节AMPK,抑制ACC和调节PPARα来调节AMPK-ACC-PPARα轴.
化合物1d表现出强大的抗炎作用,减轻肝脏炎症.

结论:

化合物1d通过AMPK-ACC-PPARα途径有效地增强肝脂代谢.
化合物1d具有显著的抗炎性质,对MASH有益.
这些综合作用使得1d化合物成为MASH的有前途的治疗剂.

关键词:

在AMPK-ACC-PPARα轴上马什 (MASH) 是一个非常重要的产品.这是一种炎症炎症炎症炎症.脂质新陈代谢脂质新陈代谢

更多相关视频

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

相关概念视频

Lipid Absorption

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Lipid Catabolism

Lipid Catabolism

Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...